Email Updates

Search form

You are here

AVAC in the News

  • The microbicides field has undoubtedly moved and shifted a lot in the past decade. Now, with first generation microbicides candidate products up and gone, antiretroviral treatment (ART)-drug based microbicides in spotlight, and only three major microbicides efficacy studies remaining, the need to lobby for increased funding of microbicides research and development, was never so compelling.

    May 14, 2010
    Citizen News Service
  • Gilead Sciences Inc. may learn this year whether its drugs for treating HIV can also stop people from catching the virus in the first place. The approach may help curb the AIDS pandemic in poor countries and bring Gilead $1 billion a year in additional U.S. sales, said Josh Schimmer, an analyst at Leerink Swann & Co. in Boston. Most investors aren’t alert to the potential benefit, he said. Researchers are compiling the first data from 10 trials involving more than 20,000 people, and initial results may be available in July.

    April 1, 2010
  • Researchers said the failure of the microbicide gels in a trial in South Africa, Zambia, Uganda and Tanzania was the last nail in the coffin for this type of prevention method.

    December 15, 2009
    New York Times
  • An antimicrobial gel tested as a method to curb the spread of HIV just proved ineffective in a major human study.

    December 14, 2009
  • A decade of increasing funding for HIV programs - in prevention, treatment and research - is paying off. Ironically, though, this good news comes at the same time that the global economic crisis and political arguments threaten the future of HIV funding.

    November 30, 2009
    Huffington Post
  • The modest protective effect of the HIV vaccine combination used in the Thai vaccine trial announced last month is statistically significant and not the result of massaging the statistics to produce a positive result, study investigators said at the AIDS Vaccine 2009 conference in Paris today.

    October 20, 2009
  • The fog around the largest AIDS vaccine study ever conducted began to lift today, as Thai and U.S. researchers for the first time publicly presented a detailed analysis of their data to over 1000 scientists gathered here at an annual meeting.

    October 20, 2009
    Science Insider
  • Researchers from the U.S. Army and Thailand announced last month they had found the first vaccine that provided some protection against HIV. But a second analysis of the $105 million study, not disclosed publicly, suggests the results may have been a fluke, according to AIDS scientists who have seen it.

    October 12, 2009
    Wall Street Journal
  • The vaccine — known as RV 144, a combination of two genetically engineered vaccines, neither of which had worked before in humans — was declared a qualified success after a six-year clinical trial on more than 16,000 volunteers in Thailand. Those who were vaccinated became infected at a rate nearly one-third lower than the others, the sponsors said Thursday morning.

    September 24, 2009
    New York Times
  • Trying to fight misconceptions about the link between H.I.V. transmission and circumcision.

    March 3, 2009
    New York Times